<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853059</url>
  </required_header>
  <id_info>
    <org_study_id>A092896</org_study_id>
    <nct_id>NCT01853059</nct_id>
  </id_info>
  <brief_title>Functional Outcomes Following Anal Cancer Treatment</brief_title>
  <acronym>FOFACT</acronym>
  <official_title>Observational Study of Functional Outcomes After Chemoradiotherapy for Squamous Cell Cancer of the Anus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bowel Disease Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anal cancer is treated with chemoradiotherapy- combined chemotherapy and radiotherapy. This
      is very successful (75% long term survival). During the course of the radiotherapy, other
      organs in the pelvis may be damaged. This can lead to long-term problems with possible
      changes to the skin, bowels with diarrhoea and incontinence problems, bladder shrinkage and
      incontinence of urine, sexual problems including impotence and ejaculatory problems, or pain
      during sexual intercourse with vaginal dryness and shrinkage. Patients should be offered help
      with these side effects. At present, there is very little information on the effect treatment
      has on a patient's quality of life, making it difficult to judge if new treatment methods are
      better.

      This project will measure quality of life from the patient's perspective after treatment for
      anal cancer. It will also gather preliminary data on quality of life after the introduction
      of a new technique for more precise 3D-targeting of radiotherapy beams at the cancer, called
      IMRT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional quality of life after chemoradiotherapy for anal cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life measured using:
General
EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30
Disease specific
EORTC QLQ-CR29
Vaizey incontinence score
MOS (Medical Outcomes Survey) sexual questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Patient-reported treatment related toxicity measured with:
Common Terminology Criteria for Adverse Events (CTCAE version 3)
Pelvis questionnaire male &amp; female (LENT/SOMA)
(LENT/SOMA: see Barraclough LH et al. Radiother Oncol; 103:327-32)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Anal Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT</arm_group_label>
    <description>Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <description>Cross-sectional analysis of patients receiving conventional radiotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under the care of the anal cancer multidisciplinary team in Addenbrookes,
        Cambridge and Christie Hospital, Manchester
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Male or Female, aged 18 years or above.

          -  Squamous cell or basaloid carcinoma of the anal canal

        Exclusion Criteria:

          -  adenocarcinoma, melanoma, lymphoma, sarcoma or other malignancy of anal canal

          -  Any synchronous or metanchronous pelvic malignancy of non-anal origin (eg. prostatic,
             genital tract)

          -  unable to complete questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Stearns, MA DPhil BMBCh MRCS</last_name>
    <phone>01603286286</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adam T Stearns</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Fearnhead</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Wilson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Jephcott</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justin Davies</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Renehan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Davidson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Saunders</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.bdrf.org.uk/</url>
    <description>Bowel Disease Research Foundation</description>
  </link>
  <reference>
    <citation>Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D. Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol. 2010 May 23;5:41. doi: 10.1186/1748-717X-5-41.</citation>
    <PMID>20492729</PMID>
  </reference>
  <reference>
    <citation>Brown MW, Brooks JP, Albert PS, Poggi MM. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. Prostate Cancer Prostatic Dis. 2007;10(2):189-93. Epub 2006 Dec 26.</citation>
    <PMID>17189954</PMID>
  </reference>
  <reference>
    <citation>Barraclough LH, Routledge JA, Farnell DJ, Burns MP, Swindell R, Livsey JE, Davidson SE. Prospective analysis of patient-reported late toxicity following pelvic radiotherapy for gynaecological cancer. Radiother Oncol. 2012 Jun;103(3):327-32. doi: 10.1016/j.radonc.2012.04.018. Epub 2012 May 23.</citation>
    <PMID>22633812</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Adam Stearns</investigator_full_name>
    <investigator_title>Specialist Registrar in Surgery</investigator_title>
  </responsible_party>
  <keyword>Anal cancer</keyword>
  <keyword>Squamous cell cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Conformational radiotherapy</keyword>
  <keyword>Intensity modulated radiation therapy</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

